View this email in your browser                            
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668596

ChiLTERN Newsletter 12

September 2018
We are pleased to bring you to ChiLTERN's twelfth newsletter, a quarterly publication sent to our ever-growing Project network. This is aimed at keeping everyone updated with the progress of the Project. With over 23 collaborators across the United Kingdom, Belgium, Spain, Italy, Switzerland, Germany, Poland, France, Norway, Sweden, the Netherlands, Ireland and the Czech Republic, our comprehensive research programme is connected to the single largest clinical trial ever to be undertaken amongst the paediatric liver cancer population. Ultimately, ChiLTERN will aim to cure more children with liver cancer, expose fewer children to toxic chemotherapy and ensure their surgery is both effective and safe.
Work Package 1 - Project Management
Contract amendments
The first contract amendment was approved by the EC in July and new Annexes are available on the Web Community Area. Beneficiaries are asked to check Annex 1 and Annex 2 documents as these detail contracted obligations with the allocated budget. Contract amendment 2 will be launched next month, and all beneficiaries have been contacted to find out if there are any changes they wish to make. 

Key dates
  • Work Package Lead teleconference  - Thursday 18th October 2018
  • ChiLTERN Internal Project Board  - Wednesday 21st November 2018 in Hiroshima,  Japan
  • SIOPEL meeting 2018 - 19th - 21st November in Hiroshima, Japan
  • ChiLTERN External Advisory Board - Tuesday 27th November 2018 in Birmingham, UK
  • End of Reporting Period 2 - Monday 31st December 2018
  • Next batch of milestones and deliverables due - Monday 31st December 2018
  • Deadline for submission of the next ChiLTERN Periodic Report to the EC - Friday 1st March 2019
Work Package 2 - PHITT Trial
Great progress is being made in Work Package 2, with 27 patients recruited to the trial and five National Coordinating Centres (NCCs) open - Republic of Ireland, Spain, Switzerland, Norway, and most recently France! To find out about the latest information, take a look at the third edition of the PHITT Clinical Trial Newsletter
Work Package 3 - Biology/Pathology
We welcome new beneficiaries who will be working within Work Package 3.
Instituto di Ricerca Pediatrica (IRP), located in Padova (Italy) has joined us and is led by principal investigator Martina Pigazzi. 
I am Martina Pigazzi and head the Molecular Genetic of pediatric leukemia at IRP. I am the Geneticist in charge of the molecular genetics at diagnosis and during follow up for all de novo Acute Myeloid Leukemia enrolled in Italy at the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP) trial, at the reference laboratory of the University of Padova. I lead a research group working on basic and translational mechanisms concerning leukemogenesis; in particular my research aims at the identification of new genetic aberrations and mutations with prognostic value to be used as biomarker to improve diagnosis definition and risk stratification of patients for moving toward a tailored adapted therapy in PDX models, for promising alternatives or complementary therapeutics to current chemotherapy. I, together with Stefano Cairo at XenTech will work on ChiLTERN Work Package 3, leading to HB PDXs to shed light into the more aggressive forms of this rare pediatric tumor for moving toward a tailored adapted therapy.
Princess Maxima Centrum (PMC), located in Utrecht (the Netherlands) has also joined us, led by principal investigator Ronald de Krijger, who will be part of the international pathologist panel.
I am Ronald de Krijger, paediatric pathologist and staff member at Princess Maxima Center for Paediatric Oncology. This is the Dutch national paediatric oncology center, where all children with cancer are centralized and treated. My focus is on solid paediatric tumours, including liver tumours, renal tumours, neuroblastomas and germ cell tumours. Our center is set up as a research hospital, with large research groups for all major tumour types, so I actively participate in ongoing research lines. For ChiLTERN, I am the national pathologist for the Dutch liver tumour cases and one of the international reviewers. I participate in Work Package 3 with a focus on bio-repository development and bio-marker studies
and in other WP3 news...................................
In the framework of the ChiLTERN Patient-Derived Xenograft (PDX) program, the first tumour engraftment from a patient enrolled in the PHITT trial took place in September 2018. A piece of tumour coming from a liver transplant in Barcelona (Spain) was sent to XenTech (Evry, France) and subcutaneously implanted in 8 immunodeficient mice in the R&D unit headed by Stefano Cairo.

Read all about how our Spanish colleagues are involved in ChiLTERN as part of the PHITT trial here.  
Work Package 4 - Validation of a clinical risk stratification for hepatoblastoma (CHIC)
There will be a CHIC meeting in Kyoto, Japan in November 2018, which will be attended by some of our ChiLTERN Work Package 4 colleagues.  
Work Package 5 - Surgery
We welcome new beneficiary MeVis Medical Solutions AG to ChiLTERN who will be working within Work Package 5.
I am Ragnar Bade, product manager at MeVis Medical Solutions AG (MMS), a leading provider of medical imaging software. In the ChiLTERN project, MMS supports Work Package 5 by creating patient individual interactive three-dimensional reconstructions and virtual resection visualisations of liver and tumours in children with solid abdominal tumours (especially in advanced liver tumours).
Work Package 6 - Toxicity of Chemotherapy
No updates to report this month
Work Package 7 - Results and Dissemination
The ChiLTERN Dissemination and Communication Plan and Publication Policy have been updated. These key documents state important information about communication and publication requirements that all beneficiaries must follow. Both documents are accessible via the Web Community Area under work package 7.   
ChiLTERN website
The ChiLTERN website is regularly updated with news and information as it is received from beneficiaries. We need to inform interested groups that our research and innovation will impact on society and people's lives by keeping these pages up-to-date and appealing. If you have any news or events relating to PHITT and ChiLTERN, do get in touch by email at so we can shout about success!
ChiLTERN on Twitter

@chilterncollab has 64 followers! As ChiLTERN progresses, social networking will allow the Project to globally expand its audience as part of the communication and promotion activities within work package 7. Please encourage others to follow @chilterncollab to showcase how our work together is achieving more than otherwise possible.  
Associate Partner News
The great news is that centres from the United Sates are now recruiting patients into the PHITT trial, coordinated by the Children's Oncology Group. By the middle of September, the USA had already recruited 10 patients and numbers are expected to increase significantly as treatment centres are approved for trial entry over the forthcoming weeks. In Japan, the regulatory processes are almost complete and the Japan Children's Cancer Group anticipate centres starting to recruit patients within the next 4-6 weeks. 
If you have any news that you would like to be included in the next edition or you know anyone who would like to receive this newsletter, please get in touch with Louise Woodall by email at by Tuesday 4th December 2018.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
University of Birmingham · University of Birmingham · Birmingham, West Midlands B15 2TT · United Kingdom

Email Marketing Powered by Mailchimp